"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Case report
peer-reviewed

Acetazolamide: Treatment of Psychogenic Polydipsia



Abstract

We are reporting a case of psychogenic polydipsia from a State of Ohio psychiatric hospital. The patient has a known five-year history of psychogenic polydipsia with recurrent hyponatremia and has been diagnosed with schizoaffective disorder bipolar type 1, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, for the past two decades. There was a marked improvement with the use of acetazolamide, resulting in a decreased compulsion to drink fluid and improvement of his hyponatremia. The patient was observed for six months. We evaluated the water balance of the patient with diurnal weight measurements (DWG) and a weekly comprehensive metabolic panel (CMP) to monitor Na⁺ levels. His symptoms and hyponatremia were improved with acetazolamide. The treatment was well tolerated without any adverse effects and improved his quality of life.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Case report
peer-reviewed

Acetazolamide: Treatment of Psychogenic Polydipsia


Author Information

Syed E. Ahmed

Heartland Behavioral Healthcare, Department of Mental Health and Addiction, State of Ohio, Northeast Ohio Medical University

Afaque H. Khan Corresponding Author

Psychiatry, Heartland Behavioral Healthcare, Department of Mental Health and Addiction, State of Ohio, Northeast Ohio Medical University


Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.


Case report
peer-reviewed

Acetazolamide: Treatment of Psychogenic Polydipsia


Figures etc.

Share
Case report
peer-reviewed

Acetazolamide: Treatment of Psychogenic Polydipsia

Syed E. Ahmed">Syed E. Ahmed, Afaque H. Khan">Afaque H. Khan

  • Author Information
    Syed E. Ahmed

    Heartland Behavioral Healthcare, Department of Mental Health and Addiction, State of Ohio, Northeast Ohio Medical University

    Afaque H. Khan Corresponding Author

    Psychiatry, Heartland Behavioral Healthcare, Department of Mental Health and Addiction, State of Ohio, Northeast Ohio Medical University


    Ethics Statement and Conflict of Interest Disclosures

    Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

    Acknowledgements


    Article Information

    Published: August 09, 2017

    DOI

    10.7759/cureus.1553

    Cite this article as:

    Ahmed S E, Khan A H (August 09, 2017) Acetazolamide: Treatment of Psychogenic Polydipsia. Cureus 9(8): e1553. doi:10.7759/cureus.1553

    Publication history

    Received by Cureus: July 21, 2017
    Peer review began: August 01, 2017
    Peer review concluded: August 01, 2017
    Published: August 09, 2017

    Copyright

    © Copyright 2017
    Ahmed et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

We are reporting a case of psychogenic polydipsia from a State of Ohio psychiatric hospital. The patient has a known five-year history of psychogenic polydipsia with recurrent hyponatremia and has been diagnosed with schizoaffective disorder bipolar type 1, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria, for the past two decades. There was a marked improvement with the use of acetazolamide, resulting in a decreased compulsion to drink fluid and improvement of his hyponatremia. The patient was observed for six months. We evaluated the water balance of the patient with diurnal weight measurements (DWG) and a weekly comprehensive metabolic panel (CMP) to monitor Na⁺ levels. His symptoms and hyponatremia were improved with acetazolamide. The treatment was well tolerated without any adverse effects and improved his quality of life.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Syed E. Ahmed

Heartland Behavioral Healthcare, Department of Mental Health and Addiction, State of Ohio, Northeast Ohio Medical University

Afaque H. Khan, M.D.

Psychiatry, Heartland Behavioral Healthcare, Department of Mental Health and Addiction, State of Ohio, Northeast Ohio Medical University

For correspondence:
hassan.khan@mha.ohio.gov

Syed E. Ahmed

Heartland Behavioral Healthcare, Department of Mental Health and Addiction, State of Ohio, Northeast Ohio Medical University

Afaque H. Khan, M.D.

Psychiatry, Heartland Behavioral Healthcare, Department of Mental Health and Addiction, State of Ohio, Northeast Ohio Medical University

For correspondence:
hassan.khan@mha.ohio.gov